GlobeNewswire·May 26, 2026, 9:05 AM ET

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine priced an underwritten public offering of 55,555,556 shares of common stock with accompanying warrants.
The combined public offering price is $2.25 per share & warrant.
Aggregate gross proceeds are expected to be approximately $125.0 million without warrant exercise.
Exercise of all warrants would generate an additional $194.4 million in gross proceeds.
Each warrant has an exercise price of $3.50 per share & expires on the earlier of 30 days after specific Phase 1 EDIT-401 clinical data disclosure or three years from issuance.
The offering is expected to close on or about May 27, 2026.
Cantor & Wells Fargo Securities are acting as joint book-running managers.
The securities are being offered pursuant to an effective Form S-3 shelf registration statement filed with the SEC.